Good Phase I results for Ebola vaccine

Bavarian Nordic announced the Phase I trial results for the Ebola vaccine (MVA-BN® RSV) co-developed with Johnson & Johnson. The trial, conducted on 75 patients, showed that the two-dose vaccine delivers a response for several years. The new vaccine will compete with the one co-developed by Merck & Co, reported to be efficacious in patients who have been in contact with an Ebola case for a short time. (Source: Bavarian Nordic)